Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway.
It is now established that 5-lipoxygenase products are synthesized and released in the airway during asthmatic reactions. The importance of these products in the asthmatic response has been established through study of the effects of 5-lipoxygenase inhibitors and leukotriene D4 receptor antagonists in patients with chronic stable asthma. In this study we review the data demonstrating that chronic administration of zileuton, an inhibitor of 5-lipoxygenase, is associated with improved airway function, decreased asthma symptoms and decreased need for asthma medication use in patients with mild to moderate asthma.
Drazen
J M
JM
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Israel
E
E
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000201:enzymology; D002908:Chronic Disease; D004311:Double-Blind Method; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*; D016037:Single-Blind Method
D000318:Adrenergic beta-Agonists; D016859:Lipoxygenase Inhibitors; C063449:zileuton; D006918:Hydroxyurea